August 31, 2016 10:30 AM ET

Pharmaceuticals

Company Overview of MOTUS THERAPEUTICS, INC.

Company Overview

MOTUS THERAPEUTICS, INC., a biopharmaceutical company, develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases. The company’s product candidate, relamorelin, is a potent, ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Its relamorelin is derived from the natural ghrelin sequence that targets the receptor for ghrelin, which is a naturally occurring hormone that plays a critical role in GI motility, digestion, and the absorption of nutrients. MOTUS THERAPEUTICS, INC. was formerly known as Rhythm Pharmaceuticals, Inc. and changed its name to MOTUS THERAPEUTICS, INC. in September 2014...

855 Boylston Street

11th Floor

Boston, MA 02116

United States

Founded in 2008

Phone:

857-264-4280

Fax:

857-264-4299

Key Executives for MOTUS THERAPEUTICS, INC.

Chairman and Chief Executive Officer
Age: 62
Founder and President
Age: 57
Founder and Member of Scientific Advisory Board
Age: 66
Chief Medical Officer
Chief Scientific Officer
Age: 61
Compensation as of Fiscal Year 2016.

MOTUS THERAPEUTICS, INC. Key Developments

Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Motus announced the completion of enrollment for a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus' ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal (GI) motility. Allergan has an exclusive option to acquire Motus Therapeutics, Inc. upon the completion of this Phase 2b study. The Phase 2b trial is designed to evaluate the effect of relamorelin on signs and symptoms of gastroparesis, GI motility, and safety in patients with diabetic gastroparesis. The randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of dosing regimens ranging from 10 to 100 mcg administered twice daily over three months. The trial enrolled 396 patients with diabetic gastroparesis at clinical sites in the U.S and Europe.

Rhythm Announces Executives Appointments

Rhythm reported that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and McGirr is former Chief Financial Officer of Cubist Pharmaceuticals.

Rhythm Appoints David Meeker, MD, David McGirr to Board of Directors

Rhythm announced that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals. David Meeker, MD, is President and Chief Executive Officer of Genzyme. David McGirr was a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals until June 2014 and a Senior Vice President and Chief Financial Officer of Cubist from 2002 to 2013.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MOTUS THERAPEUTICS, INC., please visit www.motustx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.